Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
about
Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression.Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?Colon delivery of budesonide using solid dispersion in dextran for the treatment and secondary prevention of ulcerative colitis in ratEvaluation of Hydrogel Suppositories for Delivery of 5-Aminolevulinic Acid and Hematoporphyrin Monomethyl Ether to Rectal Tumors.New lessons: classic treatments, expanding options in ulcerative colitis.Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence.Time-controlled oral delivery systems for colon targeting.Modulation of Apoptosis and Differentiation by the Treatment of Sulfasalazine in Rabbit Articular Chondrocytes.Azo compounds in colon-specific drug delivery.Oral budesonide for the therapy of post-liver transplant de novo inflammatory bowel disease: a case series and systematic review of the literature.Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease.Using liposomes to target infection and inflammation induced by foreign body injuries or medical implants.An evidence-based systematic review on medical therapies for inflammatory bowel disease.Topical therapies in inflammatory bowel disease.Interactions between Trichinella spiralis infection and induced colitis in mice.A novel dissolution media for testing drug release from a nanostructured polysaccharide-based colon specific drug delivery system: an approach to alternative colon media.Development of novel budesonide pellets based on CODES(TM) technology: In vitro/in vivo evaluation in induced colitis in rats.Effects of budesonide on P-glycoprotein expression in intestinal cell lines.Assessment of isomalt for colon-specific delivery and its comparison with lactulose.Development and evaluation of a novel pellet-based tablet system for potential colon delivery of budesonide.Pectin Film Coated Pellets for Colon-targeted Delivery of Budesonide: In-vitro/In-vivo Evaluation in Induced Ulcerative Colitis in Rat.Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update.The influence of Surelease and sodium alginate on the in-vitro release of tamsulosin hydrochloride in pellet dosage form.Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis.5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers.Intestinal organoids containing poly(lactic-co-glycolic acid) nanoparticles for the treatment of inflammatory bowel diseases.The role of gut microbiota in the modulation of drug action: a focus on some clinically significant issues.Dissolution of mesalazine modified release tablets under standard and bio-relevant test conditions.
P2860
Q33406895-4BA451FF-45A1-46FE-A9F4-0B57455D1FEBQ33868970-0D879EE5-84FD-42C3-8A5F-201F960522A5Q34786414-8788E438-4C4F-45B1-AACF-72293FB477B0Q36165888-2683F690-AE33-4044-93C1-FF2435E836BEQ36440548-194926F6-8FAD-4382-84F3-D860E744C5B4Q36580628-0C502F68-36B2-4E3B-AAFC-CF1849C2668AQ36583724-53E13958-8B46-4D06-BA42-4B7F51941CD8Q36832831-7B2C68D3-D00E-40B7-BDBA-D02A84039200Q36945853-6C7C10B2-65FF-4090-910C-2663F517BF80Q37212963-F60030CE-9C9D-43DF-894D-BB78C12EDDFCQ37414672-0EA33D3C-019D-4E68-8AB3-FD18DCF49094Q37790712-DE96FAF7-A49F-447C-B54F-95F2759DE06EQ37862584-373631FC-3F1F-4604-9990-57C15F9703A9Q38050885-0ACF4BDB-1E78-4E54-9CA8-F0D3A0779702Q38881720-17FB7566-441D-48E5-8BE0-FF3BF6984069Q39344860-D822258E-28CF-413A-B152-DA5425C00063Q39642034-ECD9DF3B-9E91-495A-9F2D-1F0034DCAD89Q40192388-7EF22482-A271-4775-8CE2-4BDA55DC2B52Q41881682-09E196FE-ADA0-4282-B969-7F811BD20B5BQ42152164-1D2845F8-01A0-4CFD-9967-801923B22D57Q42927686-8F9BCF55-6DDB-438C-89C3-76BD3E712869Q45861878-82994580-40B7-4C59-8AF6-1E3360D58814Q46559881-96832553-EB6F-4EE6-BEE9-4F0F6E52EB54Q46674905-BA80715C-D52A-40B8-A263-2177A511941FQ46879612-F6CBA2F9-D356-4220-904B-8B339117F723Q47262860-24F4314C-B675-4FD6-9BD7-F6B9866C065BQ50054146-D248324D-473C-4E89-8777-C29C90CE7B04Q53347908-622049B8-AB09-4727-A9CA-D5B8739C1516
P2860
Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
@ast
Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
@en
type
label
Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
@ast
Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
@en
prefLabel
Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
@ast
Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
@en
P1476
Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
@en
P2093
Matthias Schwab
Ulrich Klotz
P304
P356
10.1016/J.ADDR.2004.08.007
P407
P577
2005-01-01T00:00:00Z